Expression profile of Bcl‐2 family proteins in newly diagnosed multiple myeloma patients

Documenti analoghi

• High‐risk features of early relapse in newly‐diagnosed multiple myeloma: The impact of cytogenetics and response to initial therapy
  di: Andrea Manubens, et al.
  Pubblicazione: (2025)
• High‐risk cytogenetic abnormalities in multiple myeloma: PETHEMA‐GEM experience
  di: Veronica González‐Calle, et al.
  Pubblicazione: (2024)
• 30‐Minute infusion of isatuximab in patients with newly diagnosed multiple myeloma: Results of a Phase 1b study analysis
  di: Enrique M. Ocio, et al.
  Pubblicazione: (2024)
• Current and future role of carfilzomib‐based quadruplet combinations as therapy for newly diagnosed multiple myeloma
  di: Ola Landgren, et al.
  Pubblicazione: (2025)
• The evolving pattern of the monoclonal protein improves the IMWG 2/20/20 classification for patients with smoldering multiple myeloma
  di: Anna de Daniel, et al.
  Pubblicazione: (2024)